Pfizer drops after weak Q4 numbers

Pfizer lost 1.96% to Rs 1260.20 at 12:17 IST on BSE after net profit fell 3.66% to Rs 56.03 crore on 2.46% decline in total income from operations to Rs 274.48 crore in Q4 March 2014 over Q4 March 2013.

The Q4 result was announced on Saturday, 3 May 2014.

Meanwhile, the S&P BSE Sensex was up 111.89 points or 0.5% at 22,515.78.

On BSE, so far shares were traded in the counter as against average daily volume of 8,225 shares in the past one quarter.

The stock hit a high of Rs 1270 and a low of Rs 1247.35 so far during the day. The stock had hit a record high of Rs 1,779 on 2 December 2013. The stock had hit a 52-week low of Rs 985 on 29 July 2013.

The stock had underperformed the market over the past one month till 2 May 2014, sliding 2.21% compared with the Sensex's 0.65% fall. The scrip had, however, outperformed the market in past one quarter, jumping 22.62% as against Sensex's 9.21% rise.

The mid-cap company has equity capital of Rs 29.84 crore. Face value per share is Rs 10.

Pfizer's net profit declined 56.11% to Rs 220.85 crore on 6% growth in total income from operations to Rs 1111.80 crore in the year ended 31 March 2014 (FY 2014) over the year ended 31 March 2013 (FY 2013).

Pfizer's revenue for the quarter was Rs 251.69 crore as compared to Rs 252.19 crore in the same period last year. The revenue for the year was Rs 1004.27 crore as compared to Rs 947.98 crore last year.

Excluding the transitional support for sales of certain animal health products, the pharmaceutical revenue for the quarter registered a growth of 6% to Rs 251.69 crore as compared to Rs 237.24 crore in the same period last year. Similarly the revenue for the year registered a growth of 5% to Rs 961.80 crore as compare to Rs 915.06 crore last year.

The profit before tax and exceptional items for the year grew by 21% to Rs 339.58 crore from Rs 279.65 crore last year.

Pfizer's pharmaceuticals product portfolio spans a wide range of therapeutic classes from vitamins supplements and nutritional to antibiotics and cardiovascular.

Powered by Capital Market - Live News